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Abstract
DNA repair is a key determinant in the cellular response to therapy and tumor repair status could play an important role in
tailoring patient therapy. Our goal was to evaluate the mRNA of 13 genes involved in different DNA repair pathways (base
excision, nucleotide excision, homologous recombination, and Fanconi anemia) in paraffin embedded samples of triple
negative breast cancer (TNBC) compared to luminal A breast cancer (LABC). Most of the genes involved in nucleotide
excision repair and Fanconi Anemia pathways, and CHK1 gene were significantly less expressed in TNBC than in LABC. PARP1
levels were higher in TNBC than in LABC. In univariate analysis high level of FANCA correlated with an increased overall
survival and event free survival in TNBC; however multivariate analyses using Cox regression did not confirm FANCA as
independent prognostic factor. These data support the evidence that TNBCs compared to LABCs harbour DNA repair
defects.
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Introduction
Triple negative breast cancer (TNBC) defines a clinical subset of
breast cancer negative for estrogen receptor (ER), progesterone
receptor (PR) and human epidermal growth factor receptor type 2
(HER2). It accounts for about 15% of breast tumors and is
characterized by an aggressive clinical course with therapeutic
resistance, high rates of local and systemic relapse, and poor
survival. This is probably due to the intrinsic biology of this type of
tumor as well as to the absence of specific targeted treatments such
as hormonal therapy used for ER positive tumors and trastuzu-
mab/lapatinib for HER2 over-expressing tumors [1,2].
TNBC encompasses more than one subtype [3,4]. Morpholog-
ically they include metaplastic, adenoid cystic and medullary like
and at a molecular level they display different mRNA profiles such
as basal and claudin type [5,6]. Cumulating evidence suggest that
the triple negative phenotype on clinical assays enriches for basal-
like cancer, but no complete overlap exists between the two groups
[7,8]. Indeed, 25% of the TNBCs are not basal-like on gene
expression profile and similarly there are basal-like tumors that are
not triple negative by immunohistochemistry.
Most of the tumors that develop in women with germline
mutations in the BRCA1 breast cancer susceptibility gene are
TNBC [9,10]. BRCA1 has a crucial role in the repair of double-
strand breaks and its mutation leads to cancer predisposition and
genomic instability [11,12]. BRCA1 related TNBCs share several
pathological features with sporadic TNBCs and cluster within the
basal subtype by gene expression profile [13]. Thus it is not
surprising that there are data suggesting that a proportion of
sporadic basal-like breast cancers may have a dysfunctional
BRCA1 pathway, due to gene promoter methylation or transcrip-
tional inactivation [13,14]. Deficits in other DNA-repair pathways,
such as base excision repair (BER) inactivation [15], MTMG
promoter methylation [16] and lack of hOGG1 [17] have been
reported in TNBCs. These tumors also exhibit higher DNA copy
alterations and loss of heterozygosity than other breast cancer
types, suggesting higher genomic instability [18–20]. These latter
data, together with the reported association between BRCA1
deficiency and TNBC, suggest that DNA repair alterations may be
important for the development of this tumor type. If this is the
case, there could have important prognostic and predictive
implications, such as the response to the currently used anticancer
agents and to novel targeted agents, as the poly-ADP-ribose
polymerase (PARP) inhibitors [21].
While tests for the evaluation of DNA repair defects in primary
cells or in clinical samples have been described [22,23], to our
knowledge validated functional assays for the quantification of the
tumor DNA repair capabilities to be used in clinical setting do not
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exist. There are however some biomarkers that, even if not
completely validated [24–27], have been used as surrogate of
DNA repair functionality, i.e. the mRNA and/or expression levels
of key proteins involved in DNA repair pathways. Aim of our
study was to evaluate in a multiparametric manner the mRNA
expression level of different key player of DNA repair pathways
(i.e. base excision repair-BER-, nucleotide excision repair-NER-
and homologous recombination- HR- and Fanconi anemia- FA) in
TNBCs compared with LABCs and to correlate with clinico-
pathological patient characteristics.
Materials and Methods
Patients and samples
150 formalin-fixed paraffin embedded core breast cancer
samples, diagnosed as triple negative (80 cases) and luminal A
(70 cases), were retrospectively collected from patients who came
to the medical observation at the Breast Care Unit, A.O. Istituti
Ospitalieri di Cremona, Italy. Ethical permission for the study was
obtained from the A.O. Istituti Ospitalieri di Cremona (Italy)
ethical committee. Written informed consent was obtained from
patients, if applicable. All the samples were anonymized by a
pathologist staff member and none of the researcher conducting
the gene expression analysis had access to disclosed clinico-
pathological data. The patients characteristics are summarized in
Table 1.
Definition of molecular classes
Tumour grade was evaluated using the modified Bloom and
Richardson method. Immunohistochemical evaluation was per-
formed on paraffin-embedded tumour samples obtained at
diagnosis. Estrogen receptor, progesterone receptor, HER2
staining were carried out at the Pathology Unit of the A.O.
Istituti Ospitalieri di Cremona, Italy. The immunohistochemical
method used for routine markers is fully described elsewhere [28].
Tumors were classified as: luminal A (hormone receptor positive:
estrogen receptor + and/or progesterone receptor + and HER2–),
and triple-negative (ER-ve, PR-ve, HER2-ve) [29].
RNA and real time
RNA was extracted from core biopses with the High Pure FFPE
RNA Micro Kit (Roche). RNA concentrations were then
measured by NanoDrop spectrophotometer and retro-transcrip-
tion to cDNA was performed using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystem) in a 96well plate, one for
each hystological subgroup. 15ug are preamplified with TaqMan
Preamp Master mix (Applied Biosystem) and with the pool of
primers used later for real time PCR reactions. Genes selected
have a key role in the BER (PARP1); in the NER pathway (ERCC1,
XPA, XPD, XPF and XPG); in the FA pathway (BRCA1, FANCA,
FANCC, FANCD2, FANCF and PALB2); in DNA damage check-
point pathway (Chk1). Optimal primer pairs (Table 2) were chosen,
spanning splice junctions, using PRIMER-3 software (http://
frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and the
specificity was verified by detecting single-band amplicons of the
PCR products. The EP Motion robot (Eppendorf) dispensed 10 ng
of cDNA in triplicate on a 384 wells plate, one for each gene and
for each subgroup. The reaction was performed with Sybr Green
PCR master mix (Applied Biosystem) and the curve of dissociation
was evaluated. A standard curve for each specific gene was
included in each plate for an absolute quantification of the copy of
RNA. Samples were then normalized using the absolute copy
number of the housekeeping gene (ciclophilin A). The two
different sample plates (TNBC and LABC) were calibrated using
inter-run calibrators samples (four different breast cancer cell lines)
to correct for run to run technical variation. The calibration
procedure was performed on a gene per gene basis.
Data and statistical analysis
The Mann-Whitney U test was chosen to compare clinicopath-
ological and gene expression data between the two groups of
TNBCs and LABCs. The median is taken as valid proxy for
expression level of all genes. Relationships between family gene
expression levels were examined using the Spearman’s rank
correlation. Each gene distribution was split into three expression
levels (low, intermediate and high level) defined by the two tertiles
calculated on patients who did not die at the end of the study. For
Figure 1. Kaplan-Meier estimates for event-free survival (panel A) and overall survival (panel B) in TNBC patients stratifies by the
different level of FANCA expression (univariate analysis, categorization based on tertiles).
doi:10.1371/journal.pone.0066243.g001
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Table 1. Baseline patients’ demographic.
CLINICAL PARAMETERS TNBC (N=80) LABC (N=70)
Follow-up time – years
Median (range) 5.5 (0.1–16.0) 3.16 (0.6–17.3)
Mean 6 SD 6.764.7 5.965.5
Age – years
Median (range) 59.5 (33.1–91.3) 66.6 (36.5–84.5)
Mean 6 SD 60.2614.4 63.1611.5
Age – no. (%)
,65 46 (57.5) 31 (44.3)
$65 34 (42.5) 39 (55.7)
Menopausal status – no. (%)
Pre- 19 (23.7) 12 (17.1)
Post- 59 (73.8) 58 (82.9)
not known 2 (2.5) 0 (0.0)
Clinical tumor size – no. (%)
#20 mm 16 (20.0) 21 (30.0)
.20 mm 36 (45.0) 12 (17.1)
not known 28 (35.0) 37 (52.9)
Tumor size at surgery – no. (%)
#20 mm 36 (45.0) 42 (60.0)
.20 mm 22 (27.5) 11 (15.7)
not known 22 (27.5) 17 (24.3)
Pathological T staging – no. (%)
T1 41 (51.3) 48 (68.6)
T2 20 (25.0) 11 (15.7)
T3 2 (2.5) 1 (1.4)
T4 4 (5.0) 3 (4.3)
not known 13 (16.2) 7 (10.0)
Pathological N staging – no. (%)
N0 37 (46.3) 66 (94.3)
N+ 18 (22.5) 0 (0.0)
not known 25 (31.2) 4 (5.7)
Metastatic status – no. (%)
M0 60 (75.0) 68 (97.1)
M1 4 (5.0) 0 (0.0)
not known 16 (20.0) 2 (2.9)
Pathological staging – no. (%)
Stage I 28 (35.0) 48 (68.6)
Stage IIA 13 (16.3) 11 (15.7)
Stage IIB 5 (6.2) 1 (1.4)
Stage IIIA 4 (5.0) 0 (0.0)
Stage IIIB 4 (5.0) 3 (4.3)
Stage IV 4 (5.0) 0 (0.0)
not known 22 (27.5) 7 (10.0)
Basal histotype – no. (%)
IDC 66 (82.5) 23 (32.9)
ILC 5 (6.2) 16 (22.9)
Other 7 (8.8) 30 (42.8)
not known 2 (2.5) 1 (1.4)
Basal tumor grade – no. (%)
Table 1. Cont.
CLINICAL PARAMETERS TNBC (N=80) LABC (N=70)
1 1 (1.2) 6 (8.6)
2 14 (17.5) 47 (67.1)
3 64 (80.1) 15 (21.4)
not known 1 (1.2) 2 (2.9)
Basal Ki67 – no. (%)
Median (range) 37 (3–90) 7.5 (1–16)
Mean 6 SD 44.6626.4 7.363.3
,10 3 (3.7) 50 (71.4)
$10 75 (93.8) 20 (28.6)
,20 15 (18.7) 70 (100.0)
$20 63 (78.8) 0 (0.0)
not known 2 (2.5) 0 (0.0)
Neoadjuvant treatment – no. (%)
Done 35 (43.8) 19 (27.2)
not done 38 (47.5) 50 (71.4)
not known 7 (8.7) 1 (1.4)
Surgical treatment – no. (%)
Mastectomy 21 (26.3) 14 (20.0)
Breast conservation 48 (60.0) 54 (77.1)
not known 11 (13.7) 2 (2.9)
Vital status – no. (%)
Alive 53 (66.2) 69 (98.6)
Dead 27 (33.8) 1 (1.4)
SD: standard deviation; IDC: invasive ductal carcinoma; ILC: invasive lobular
carcinoma.
doi:10.1371/journal.pone.0066243.t001
Table 2. Real Time PCR primers.
GENE PRIMER F PRIMER R
CICLOPHILIN A GACCCAACACAAATGGTTCC
TTTCACTTTGCCAAACACCA
PARP1 AAGAAATGCAGCGAGAGCAT CCAGTGTGGGACTTTTCCAT
ERCC1 GGCCTATGAGCAGAAACCAG TTCACGGTGGTCAGACATTC
XPA GAACCACTTTGATTTGCCAAC TTGTTTTGCCTCTGTTTTGG
XPF GAGAAATCTTTTTGTGAGGAAACTG CAACTTCAGGTTTGTGCTGTTC
XPG AAGCCATCAAAACTGCCTTC TCGTTTTCTCTTCGAACTTGG
XPD GTGGCCATCAGCTCCAAAT CAGCAGGAGGTTCCCATAGT
BRCA1 GCCAGAAAACACCACATCAC CAGTGTCCGTTCACACACAA
FANCA GAGGTTCTTCAGTCATACCCTGA TCTCTCTGCATCTGAACAGCA
FANCC CCAGCCAGAGTTCTTTGAGG CGAAGCCAGAGGCAGACTAC
FANCD2 CCCATCTGCTATGATGATGAA CGTATTTGCTGAGGGGATATG
FANCF GCTAGTCCACTGGCTTCTGG GGTGGCGGCTAGTCACTAAA
PALB2 TGGGACCCTTTCTGATCAAC GGGGCATCAAAAATTGGTTT
CHK1 GGTCACAGGAGAGAAGGAAT TCTCTGACCATCTGGTTCAGG
doi:10.1371/journal.pone.0066243.t002
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further testing, each gene distribution was dichotomized (low and
high level) using the median gene expression value as the cut-off
point. Consistently, patients were divided into different subgroups
based on different gene expression level. Univariate comparisons
for all categorical variables were performed by Pearson’s chi-
squared test with Yates’s correction for continuity or Fisher’s exact
test, when appropriate. Overall survival (OS) and event-free
survival (EFS) were classified as outcome measures and defined as
the length of time from the start of neoadjuvant chemotherapy or
the date of curative surgery (in patients treated with only adjuvant
therapy) or the date of diagnosis (in patients diagnosed with
metastases) to the last follow-up date or death (irrespective of the
cause) or to the first relapse or progression event. OS and EFS
curves were plotted with the Kaplan-Meier method. The log-rank
test and Cox proportional hazard models were used to compare
time-to-event distributions between subgroups. All analyses were
performed using SPSS (version 10.0– Chicago, IL) and STATIS-
TICA software system (version 6– Tulsa, OK). All tests were
performed two-sided and p values ,0.05 were considered
statistically significant.
Results
Patients’ characteristics
We considered a cohort of 150 paraffin embedded core biopsies,
80 with a pathological diagnosis of TNBC and 70 with a diagnosis
of LABC that came to the medical attention of a single medical
center, the Breast Care Unit of A.O. Istituti Ospitalieri di
Cremona from January 5th, 1995 to August 19th, 2008. The two
groups (TNBC vs LABC), whose characteristics are depicted in
Table 1, were comparable in terms of age (p = 0.2056) and
menopausal status at diagnosis (p = 0.4493), surgical treatment
(p = 0.3200), pathological T staging at surgery (p = 0.1404), and
follow-up time (p = 0.0649).
mRNA expression of the 13 genes involved in DNA repair
pathways
Genes involved in different DNA repair pathways were studied
by RT-PCR and Table 3 summarizes the data for both TNBC
and LABC. There was considerable variability in expression levels
in the individual genes. The levels of the NER genes, ERCC1,
XPA, XPF and XPD genes were significantly lower in TNBCs than
in LABCs, while there was no difference for XPG. FA genes were
less expressed than NER genes in TNBC. BRCA1, FANCD2,
FANCF and PALB2 genes were significantly less expressed in
TNBCs than in LABCs. CHK1 gene was significantly less
expressed in TNBCs than in LABCs. On the contrary, PARP1
levels were higher in TNBCs than in LABCs.
Table 4. Significant p values for the association between gene expression and clinic-pathological characteristics of triple negative
breast cancer patients (univariate analysis, categorization based on tertiles).
PATHWAY GENE pT classification pN classification Vital status
at surgery at surgery at last follow up
BER PARP1
NER ERCC1
XPA
XPF 0.0162
XPG 0.0437
XPD
FA BRCA1
FANCA 0.0366 0.0144
FANCC
FANCD2
FANCF
PALB2
SENSOR CHK1
doi:10.1371/journal.pone.0066243.t004
Table 3. Normalized and calibrated values (mean 6 SD and
median) of the different DNA repair genes in tumor samples.
PATH
WAY GENE TNBC (N=80) LABC (N=70) p value*
Mean ± SD Median Mean ± SD Median
BER PARP1 10.87610.92 8.250 7.0565.46 5.221 0.0002
NER ERCC1 0.7160.66 0.633 6.87620.77 1.040 ,0.0001
XPA 0.1060.08 0.080 0.1660.21 0.104 0.0309
XPF 23.35655.61 5.108 68.936107.05 21.996 ,0.0001
XPG 0.6660.71 0.468 1.5163.52 0.287 0.1534
XPD 0.27660.360 0.186 6.68610.26 3.662 ,0.0001
FA BRCA1 0.02860.025 0.020 0.8363.36 0.062 ,0.0001
FANCA 0.13860.279 0.057 0.2760.71 0.094 0.8293
FANCC 0.00560.007 0.003 0.00260.050 0.003 0.3627
FANCD2 0.0860.124 0.054 4.45623.32 0.150 ,0.0001
FANCF 0.02660.027 0.018 0.45161.170 0.031 ,0.0001
PALB2 0.45360.563 0.306 5.91623.03 2.010 0.0006
SEN
SOR
CHK1 0.17960.300 0.108 11.51646.44 1.779 ,0.0001
*p value indicate the difference of the gene expression levels between TNBC anl
LABC; p value in bold are significant.
doi:10.1371/journal.pone.0066243.t003
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Association between gene expression and clinic-
pathological characteristics
Table 4 reports the p values found between the gene expression
level based on tertiles (low, intermediate and high level as specified
in Materials and Methods) and some clinic-pathological charac-
teristics in TNBC. Lower levels of XPG and FANCA were
associated with higher pathological T classification at surgery
(pT2-4 vs pT1); higher level of XPF was associated with no lymph
node involvement (pN0 vs pN1-3), and higher levels of FANCA
correlated with vital status. Using the median gene expression
value as a cut-off point of categorization (low and high level), only
the association of XPG and FANCA expression levels with pT
classification remained statistically significant. No other associa-
tions were found among the other clinic-pathological evaluated
parameters (age at diagnosis-65 years vs $65 years-; menopausal
status-pre-menopausal vs post-menopausal-; clinical dimension at
diagnosis-#20 mm vs.20 mm-; basal histotype-ductal infiltrating
carcinoma vs others-; basal grading-G1-2 vs G3-; basal Ki67-
,14% vs $14% and ,20% vs $20%-; clinical complete
response-cCR vs not cCR-; pathological complete response-pCR
vs not pCR-). When the same analysis was performed in the LABC
cohort of patients, none association could be found.
We correlated the different gene expression levels based on
tertiles with OS and EFS. As depicted in Table 5, the intermediate
level of XPG correlated on univariate analysis with increased OS
compared to the low level. Interesting enough, the high level of
FANCA correlated with an increased OS and EFS compared to the
low level. Again, the intermediate level of FANCA correlated with
an increase in EFS compared to the low level. The Kaplan-Meier
curves (Figure 1) shows that higher level of FANCA correlated with
an increased OS (p = 0.0153) and an increased EFS (p = 0.0207).
Furthermore, using the median gene expression value as a cut-off
point of categorization, we again found a trend (not significant)
toward better OS (p = 0.0906) and EFS (p= 0.0999) in patients
with high level of FANCA. Multivariate analyses using Cox
regression, however, showed that the FANCA expression level was
not an independent prognostic factor in TNBC patients adjusted
for the potential confounding factors: age at diagnosis, surgical
treatment, pathological T and N staging at surgery. As regards
LABCs, OS and EFS data were not yet mature.
Discussion
TNBC represents a subset of breast cancer with well
documented poor prognosis, whose real causes are still to be
defined even if a number of adverse factors have been advocated,
such as the fact that these tumors are at the diagnosis commonly of
high nuclear mitotic grade, of larger tumor size and with a more
aggressive expression profile (low BCL2 and high p53 and Ki67
expression) [5,30,31]. Several studies have demonstrated signifi-
cant lower EFS in patients with TNBC compared to patients with
non-TNBC; in addition, shorter OS in TNBC patients is widely
reported [3,32–34]. Despite the poor prognosis, these tumors are
particularly chemosensitive at least in a short-term time frame
[35,36]. In fact, patients with TNBC have increased pathologic
complete response (pCR) rates compared to non-TNBC patients
after treatment with taxanes and antracycline agents. Wang at al
reported a 38% of pCR in TNBC and 14% in non-TNBC patients
treated with taxane in combination with antracycline [37]. Better
response rates were also reported after treatment with alkylating
agents, including cyclophosphamide, cisplatin, and carboplatin
[38].
TNBC have been shown to harbour DNA repair deficiencies,
including BRCA1 dysfunction, due to promoter methylation or
deregulation of other genes involved in their transcriptional
regulation [9], BER inactivation [15], MTMG promoter hyper-
methylation [16] and lack of hOGG1 [17]. Given the importance
of the cellular DNA repair in determining the cellular response to
different anticancer agents [39–43], a priori knowledge of the repair
status of a given tumor could play an important role in selection of
the most appropriate therapy. Attempts to investigate the
functionality of a given DNA repair pathway have been
undertaken and shown to be feasible. Willers et al reported the
successful detection of BRCA1, FANCD2 and RAD51 foci in seven
breast cancer biopsies irradiated ex vivo, suggesting the possibility to
detect defects within the complex FA/BRCA DNA damage
response pathway [44]. Isolation of epithelial cells from breast
tumor specimens and application of specific functional DNA
repair assay systems led to the detection of specific defects in
double strand breaks repair [22], while homologous recombina-
tion status could be determined in ovarian cancer samples by
Table 5. Overall survival and event-free survival in triple
negative breast cancer patients by expression of the different
genes (univariate analysis, categorization based on tertiles).
TNBC (N=80)
PATHWAY GENE EXPRESSION OS EFS
p value p value
BER PARP1 II-I terziles 0.3056 0.2334
III-I terziles 0.6140 0.4632
NER ERCC1 II-I terziles 0.9993 0.9450
III-I terziles 0.1868 0.3955
XPA II-I terziles 0.2035 0.0957
III-I terziles 0.7071 0.9908
XPF II-I terziles 0.7813 0.9566
III-I terziles 0.1088 0.4704
XPG II-I terziles 0.0344 0.0674
III-I terziles 0.2870 0.2902
XPD II-I terziles 0.1010 0.0764
III-I terziles 0.1403 0.2480
FA BRCA1 II-I terziles 0.4812 0.6162
III-I terziles 0.4196 0.5115
FANCA II-I terziles 0.1088 0.0408
III-I terziles 0.0045 0.0141
FANCC II-I terziles 0.3579 0.5383
III-I terziles 0.0850 0.0736
FANCD2 II-I terziles 0.0845 0.1352
III-I terziles 0.1554 0.2216
FANCF II-I terziles 0.7556 0.9254
III-I terziles 0.6192 0.7587
PALB2 II-I terziles 0.5170 0.5381
III-I terziles 0.2010 0.1617
PARP1 II-I terziles 0.3056 0.2334
III-I terziles 0.6140 0.4632
SENSOR CHK1 II-I terziles 0.7740 0.4396
III-I terziles 0.2325 0.2601
The mRNA expression distribution of all the genes was split into three groups,
as described in Materials and Methods. p value in bold are significant.
doi:10.1371/journal.pone.0066243.t005
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RAD51 foci formation after in vitro treatment with a PARP
inhibitor [23]. However, all these assays still need to be technically
improved (ie. requirement for an automated foci scoring and
setting up of tumor specific primary cultures) rendering difficult
their wide spread clinical use. An alternative approach is the study
of biomarkers that, even if not completely validated [24–27], can
be considered surrogate of DNA repair functionality, i.e. the
mRNA and/or expression levels of key proteins involved in DNA
repair pathways.
The expression profile of a number of genes involved in the
different DNA repair pathways was studied in a cohort of TNBC
samples as a surrogate markers of DNA repair status and
correlated with different clinic-pathological characteristics, includ-
ing survival. These data were compared to the ones obtained in a
group of patients with LABC, that represent the breast cancer
subtype with the best prognosis.
The levels of expression of all the genes involved in the NER
and FA pathways were significantly lower in TNBC as compared
to LABC samples, with the exception of XPG, FANCA and FANCC
whose difference did not reach a statistically significant value.
These expression data might in part explain the extremely high
sensitivity of TNBC patients to chemotherapy. It has in fact been
demonstrated that not only the deficiency, but also low levels of
mRNA/protein involved in NER, i.e ERCC1 and XPF or FA genes
are associated with increased sensitivity to alkylating agents in
different cellular systems [45]. At the same time, the low
expression level of these genes might explain the bad prognosis
of the tumors, even if they do respond well to chemotherapy. The
low DNA repair capacity would in fact increase the genomic
instability of the tumor cells enabling them to accumulate much
more mutations through which cells would became more
aggressive. Sporadic stage I breast cancer have recently been
reported to exhibite a significant deficiency of NER capacity
relative to epithelial control tissue [46] by both functional
unscheduled DNA synthesis and mRNA expression of NER
genes. Low expression of 4 proteins – XPF, FANCD2, MLH1 and
pMK2– assessed in FFPE tumor specimens by semiquantitative
immunohistochemistry, was associated with shorter recurrence
free survival in multivariate analysis [47], corroborating the idea
that tumors with reduced DNA repair capacity will have a higher
degree of genomic instability and therefore behave more
aggressively.
The data on FANCA are, on the contrary, counter-intuitive and
intriguing. FANCA was not differentially expressed between TNBC
and LABC, but it was found to positively correlate in univariate
analysis with both EFS and OS (higher level correlated with longer
EFS and OS). FANCA is one of the 13 proteins cooperating in a
common DNA repair pathway (for rev see [48,49]). FANCA,
higher expression correlated with an improved outcome that could
be a consequence of a less malignant phenotype, due to a more
stable tumor genome. This resembles what observed for the
expression of ERCC1 in non small cell lung cancer (NSCLC),
where it has been shown that higher ERCC1 levels were correlated
with a better prognosis [50,51], but was also higher levels of
ERCC1 were a marker of resistance to a platinum containing
regimens [50]. Recently, the experimental finding that ERCC1
negative NSLC samples display a higher genomic instability
corroborate the more unstable and then the worst clinical history
of ERCC1 low/negative tumors [52].
There are few, but contrasting data, on CHK1 expression in
different breast cancer subtypes. CHK1 is a kinase that has an
important role in both the maintenance of genomic instability and
in the transduction pathways after DNA damage [53]. Verlinden
et al. [54] reported a twofold higher expression (as assessed by
RT-PCR) of CHK1 in grade 3 TNBC than in other grade 3 tumor
breast subtype; while no difference CHK1 protein expression was
found in different breast cancer cell lines. These discrepancies can
be related to the different methodologies used (RT-PCR vs
western blotting; relative vs absolute RT-PCR values), samples size
and the pathological classification of the different tumor analyzed.
All tumor samples analyzed expressed PARP1mRNA, whose levels
were higher in TNBC compared to LABC, reinforcing the data
that neoplastic tumors express high level of PARP [55,56].
There are a number of issues that limits the present study: i.e. its
retrospective nature, the relative small sample size and the fact it
analysed the mRNA expression levels of DNA repair protein
rather than the quantification of a functional DNA repair status.
Nevertheless, our data are the first to show the mRNA expression
of multiple DNA repair genes involved in three different DNA
repair pathways (BER, NER and FA) in a cohort of TNBC and
LABC.
These data support the experimental evidence that TNBC
harbour DNA repair defects and this could explain both the
extremely chemo-sensitivity of this tumor type to chemotherapy in
a short term and the worse outcome probably correlated with the
inability to counteract the increased genomic instability for the
lack of an efficient DNA damage status.
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